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Adult stem cells have generated great amount of interest amongst the scientiﬁc community for their potential therapeutic
applications for unmet medical needs. We have demonstrated the plasticity of mesenchymal stem cells isolated from the umbilical
cord matrix. Their immunological proﬁle makes it even more interesting. We have demonstrated that the umbilical cord is an
inexhaustible source of mesenchymal stem cells. Being a very rich source, instead of discarding this tissue, we worked on banking
these cells for regenerative medicine application for future use. The present paper gives a detailed account of our experience in the
establishment of a mesenchymal stem cell bank at our facility.
1.Introduction
Stem cell research and science is likely to oﬀer a second
generation of drugs, for hitherto untreatable clinical disor-
ders. Regenerative medicine centers all over the world are
working on diﬀerent cell types to meet this need. The ethics
issues and other controversies around the embryonic cells
make it a less interesting candidate for clinical applications.
Other newer sources of stem cells are induced pluripotent
stem cells (iPS cells). The generation of human iPS cells
from adult stem cells makes it possible to produce patient-
speciﬁc ES-like stem cells for therapeutic purposes. But there
are several issues on the processes adopted to produce the
cells of interest, so it is still in the research level. In sharp
contrast, progress with adult stem cells has been impressive.
They would have a broader diﬀerentiation capacity than
previously thought, since they give rise to cell types of
multiple tissues [1].
Among all adult stem cell types, the bone-marrow-
derived mesenchymal stem cells (BMMSCs) have been the
most extensively studied cell type so far [2–4]. Bone marrow
aspiration is invasive and painful; moreover, cell yield and
diﬀerentiation potential of MSCs could decline with age
[5, 6]. Amongst several other sources studied, umbilical cord
blood is another source of mesenchymal stem cells, but the
low frequency of MSCs in cord blood makes it less attractive
[7–9].ThusculturingandderivingMSCsfromallcordblood
units is less interesting and may not be rewarding [10–
12]. We have studied umbilical cord tissue which provides
a unique source of mesenchymal stem cells (MSCs) with
immense potential for tissue repair [13–15]. Collection of
umbilical cord is easy, with no ethical concern, and does not
harm newborns and the mothers. The plasticity of umbilical
cord MSC (UCMSC) has been previously demonstrated by
our group [15]. UCMSCs can be expanded, are remarkably
stable,anddonottriggeranystrongimmuneresponse.Their
immunomodulatoryactionopensanewdirectiontopossibly
reduce the rejection in allogeneic transplantation situations
[16].Theimmensepotentialsofthesecellsforpossiblefuture
regenerative medicine applications can, therefore, not be
overlooked. The plasticity and expandability of these cells at
a distant future, even after prolonged cryopreservation, is an
additional attraction. All these make UCMSCs bankable and
usable.
We did extensive testing on these cells to ensure their
safety, pluripotency, and eﬃcacy after prolonged storage
periods. Here, we share our experience on all the aspects of
MSC banking.2 Stem Cells International
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Figure 1: (a) Migration of UCMSCs from the explants after 10–15 days, (b) UCMSCs form a monolayer of adherent ﬁbroblast-like cells by
day 25.
Table 1: Parameters of all the ﬁve cords studied.
Sample no. Mothers age Sex of baby Gestation
(weeks)
Cell count
at P1 (106)
(1) 25 Female 40 45
(2) 39 Male 39 50
(3) 32 Male 38 42
(4) 24 Female 38 40
(5) 28 Male 40 47
2.Objectives
The main objectives of banking cells from this source were
(1) to develop a mesenchymal stem cell bank that would
ensure availability of high-quality, reliable-and-well
characterized human mesenchymal stem cells for
clinical application,
(2) to optimize the cell numbers at the master and
working cell bank levels,
(3) to establish stability studies at diﬀerent time points
during the deﬁned storage period,
(4) toestablishthefunctionalcapabilityofcellsstoredfor
varying periods in liquid nitrogen,
(5) to put in place documentation formats for raw
material procurement, manufacturing process, qual-
ity control, quality assurance and deviation if any,
(6) establish a comprehensive quality management sys-
tem to support the cGMP facility requirements
throughout the process of cell banking.
3.MaterialandMethods
3.1. Informed Consent. The signiﬁcance of the consenting
process cannot be underestimated. An informed consenting
procedure was administered to few pregnant women by our
trained staﬀ or the obstetricians themselves. At antenatal
clinics,thesemothersweregivenaleaﬂetwhichexplainedthe
cord tissue banking process and the potential use of UCMSC
as an alternative for a possible future clinical application.
The obstetricians or the trained staﬀ discussed the project
Table 2: Range and median of surface marker expression of
UCMSC as detected by ﬂow cytometry. Data of all ﬁve cords
processed.
CD Markers Range (%) Median (%)
CD73 99.11–99.79 99.46
CD105 99.81–100 99.95
CD44 99.32–100 99.57
CD29 95.47–99.4 99.90
CD45 0.15–2.15 0.2
CD14 0–0.9 0.24
CD31 0–0.63 0.08
vWF 0–3.23 0.14
HLA-DR 0.24–2.3 0.42
HLA-ABC 75.62–99.82 99.46
SSEA-4 45.96–94.38 76.6
with the mother, answering any queries that arose. Each
mother responded to questions in a donor evaluation form
which was designed to ascertain the risk of transmissible
diseases, both infectious and genetic. Parents were given the
opportunity to read the information prior to delivery and to
make an informed choice to donate the umbilical cord for
research. They were given the full liberty to refuse collection.
Mothers gave a written consent for the collection of cord
tissue postpartum and also gave consent to provide blood
samples for all the mandatory tests. The protocol of the
informed consent was approved by the Institutional Stem
Cell Committee.
3.2. Raw Material Collection and Transportation. Cord-
tissue-derived stem cell banking basically involves three
importantsteps:collection,processing,andcryopreservation
of tissue derived stem cells.
The cord tissue collection process was relatively simple,
safe painless and was done just immediately after child birth.
The cord was clamped and cut and 15cms of the cord
was transferred into a labeled tube containing the collection
mediasupplementedwithantibiotics.Aspecializedvalidated
temperature controlled container (2–15◦C) was given to
those parents who had chosen to donate their child’s MSCs
for this speciﬁc standardization. The collection kit with theStem Cells International 3
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Figure 2: UCMSCs expressed mesenchymal markers and were negative for hematopoietic and endothelial markers.
cord was transported to the processing facility within 36hrs.
On arrival at the processing facility, the sample was allocated
a barcode that enables it to be tracked right throughout
processing and banking.
3.3. Infectious Disease Testing. Before processing the umbil-
ical cord tissue, the maternal blood was screened for infec-
tious disease markers like HIV I & II and HCV antibodies,
HbsAg, Syphilis, and CMV IgG and IgM as per existing
regulatory guidelines. If maternal blood was reactive for
any of the infectious diseases, it was not taken up for
standardization. Increased levels of CMV IgG, were not
a disqualiﬁcation. The cord tissue was then processed for
isolation and characterization of stem cells.
3.4. Processing Facility. All the samples were processed in
the company’s GMP-compliant facility comprising of self-
contained Grade B cell processing suites. Each processing
suite has a Class II microbiological safety cabinet providing
the Grade A air environment required for open processing of
cell materials. The suites are self-contained and independent
of each other in order to minimize the chances of cross-
contamination. Each suite is capable of operating indepen-
dently. All liquid nitrogen storage containers were kept in a
separate room along with controlled rate freezers which were
used for cryopreservation of the derived UCMSCs.
3.5. Cord Tissue Processing. Five cord tissues were used for
the standardization process. Only seven to eight cms of the
cord was used. Only clean, glistening, nonsuppurative, non
contaminatedtissuesweretakenupforprocessing.Thecords
were washed with phosphate-buﬀered saline supplemented
with antibiotics. Approximately twenty tissue explants of
about 2mm size each were plated in tissue-culture-grade
petri dishes containing DMEM/F12 with fetal bovine serum
supplemented with FGF. The dishes were left undisturbed
in a 5% CO2 incubator maintained at 37◦Cf o r4 - 5d a y s
after which fresh culture medium was added to the dishes.
Adherent cells were allowed to expand for 10–15 days by
changing the media at an interval of 2 days. The cells were
harvested at 80–90% conﬂuency using TrypLE Select. A cell
count was performed after harvesting the cells, and about a
million cells were replated into 300cm2 tissue culture ﬂasks
for further expansion. All reagents used were quality assured,
and, in the house quality assurance approvals were obtained
prior to usage as per cGMP guidelines.
3.6. Generation of Master and Working Cell Banks. At all
steps,adetailedconsumptionofthemediaandreagentsused
for processing was recorded. Appropriate batch numbers,4 Stem Cells International
Table 3: Stability data of UCMSCs from all ﬁve cords at diﬀerent time points.
Sample no. Parameters Time points
Initial 1 month 6 months 1 year 2 years 3 years
Sample 1
Cell count (106) 12.0 11.8 11.2 11.1 11.6 10.8
Viability (%) 98.9 98.3 98.1 98.8 97.7 98.3
Immunophenotype (CD73 & CD105) (%) 98.0 98.0 98.0 98.0 98.0 98.0
Sample 2
Cell count (106) 20 19.7 19.4 19.5 19.2 19.1
Viability (%) 99.5 99.2 99.2 99.0 98.9 98.9
Immunophenotype (CD73 & CD105) (%) 98.0 98.0 98.0 98.0 98.0 98.0
Sample 3
Cell count (106) 5.0 5.0 4.8 4.6 4.7 4.5
Viability (%) 99.8 99.7 99.8 99.6 99.5 99.5
Immunophenotype (CD73 & CD105) (%) 98.0 98.0 98.0 98.0 98.0 98.0
Sample 4
Cell count (106) 1.0 1.0 1.0 1.1 1.0 1.0
Viability (%) 98.7 98.7 98.5 98.6 98.5 98.5
Immunophenotype (CD73 & CD105) (%) 98.0 98.0 98.0 98.0 98.0 98.0
Sample 5
Cell count (106) 15.5 15.2 15.0 15.0 15.1 15.0
Viability (%) 98.0 98.1 97.8 97.8 97.6 97.5
Immunophenotype (CD73 & CD105) (%) 98.0 98.0 98.0 98.0 98.0 98.0
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Figure 3: UCMSCs did not show expression of HLA-DR pre- and postcryopreservation.
were assigned to the cell banks. In order to ensure supply
of adequate cells for future requirement, a master cell bank
and working cell bank concept was adopted. This two-tiered
cellbankingsystemwasalsofeltsoastooptimizethespacein
theliquidnitrogenstoragecontainers.Thus,inallthecases,a
mastercellbankwasplannedfromwhichaworkingcellbank
w a st ob em a d ef o rf u t u r eu s e .E a r l i e rw eh a v ep u b l i s h e do u r
data on immunophenotyping, diﬀerentiation potential, and
karyotyping of UCMSCs expanded till passage 8 that helped
us come up with a suitable strategy to bank these cells [15].
Time taken to culture and harvest adequate cell numbers was
noted down with the variables that aﬀected the numbers. At
all times, storage of the cells was planned in 1.8mL-capacity
cryovials.Stem Cells International 5
3.7. Quality Control Tests Performed. All samples underwent
the following quality control tests based on available interna-
tional guidelines:
(1) cell enumeration (2) phenotypic characterization,
(3) viability determination, and (4) microbiological tests for
sterility, mycoplasma, endotoxin levels on the cell super-
natants.
(1) Cell Enumeration. Cell counts were taken using an
automated cell counter. For generation of a master cell bank,
cells were frozen at passage 1. From the master cell bank, a
working cell bank was created to ensure that adequate cells
can be further derived as per requirements.
(2,3) Phenotypic Characterization and Viability Determina-
tion. Cellsfromeachpassageweresubjectedtoimmunophe-
notypic analysis. Cultured cells were incubated with various
mouse anti-human antibodies conjugated to either FITC,
PE, or PerCP. Antibodies used were CD45, CD73, CD105,
SSEA-4, HLA-DR, HLA-ABC, CD31, CD14, CD44, CD29
and vWF. While all antibodies were procured from BD
Pharmingen, USA, only CD105 antibody was procured from
Caltag Laboratories.
After incubation for 20mins at 4◦C, the cells were
washed with PBS and acquired using a FACS Calibur
ﬂow cytometer (Beckton Dickinson). Cell viability was also
determined by staining the cells with 7-AAD (7 Amino
Actinomycin D) and analysed using a FACS Calibur ﬂow
cytometer. Non-speciﬁc ﬂuorescence was determined by
staining the cells with directly conjugated isotype-matched
anti-mouse monoclonal antibodies. Approximately 10,000
events were acquired and data analysis was performed using
the CellQuest software.
(4) Microbiology Tests. To detect the presence of aerobic and
anaerobic microbes, sterility testing was done on the cell
washsample.Thistestwasperformedbyinoculatingsamples
in two diﬀerent sterile nutrient mediums, namely, Fluid
Thioglycolate Medium (FTM) and Soybean Casein Digest
Medium (SCDM).
The Limulus Amebocyte Lysate (LAL) test is a qualitative
test for Gram-negative bacterial endotoxin. Limulus Ame-
bocyte Lysate was reconstituted with LAL reagent water and
then mixed in equal parts with the sample. After incubation,
and in the presence of endotoxin, gelation occurs; in the
absence of endotoxin, gelation does not occur. Sterility and
endotoxin testing were performed on the cell wash samples
obtained at the time of harvest.
Mycoplasma detection was done by semi quantitative
PCR which is the method of choice for detection of
mycoplasma contamination in cell cultures. Commercially
available kit (Minerva Biolabs, GmbH) was used for the
detection of mycoplasma in the cell culture supernatant.
During the banking process, segregation of fully tested
samples from untested samples was ensured by using two
separate liquid nitrogen storage containers housing “Quar-
antined” and “Ready for use” samples with the correspond-
ing labels. Quarantined samples are transferred to the ﬁnal
storageafterreceiptofallthereports.Oncethecellsareready
for use, a certiﬁcate of analysis was generated.
3.8. Stability Studies. Stability studies were designed and
conducted to determine the optimum period for which the
UCMSCs can be cryopreserved without having any eﬀect
on viability. For this, UCMSCs were isolated and expanded
in cell culture media. After expansion, approximately 1–
2 0m i l l i o nU C M S C sw e r ef r o z e np e rc r y o v i a la n ds t o r e d
in liquid nitrogen. Cells were frozen at a controlled rate
to minimize freeze-related trauma. Before freezing, the cell
count, viability, and immunophenotyping were done. At
speciﬁed time points (1 month, 6 months, 1 year, 2 years,
and 3 years), the cryovials were thawed in a 37◦Cw a t e r
bath. Once thawed, the cell count was taken using an
automated hematology analyzer. Immunophenotyping and
viability assessment were done immediately postthawing
using a ﬂow cytometer. Karyotyping was performed on the
cells from every passage up to passage 8, and this has already
been published earlier [15].
3.9. Documentation. Documentation, an integral part of any
process, is very important to develop proper processing
steps.Usingtheinternationalguidelinesavailable,allrelevant
information and tests relating to the raw materials were
performed at various stages, and the results thereon were
documented for each sample in the batch manufacturing
record (BMR). The batch manufacturing record, thus,
developed was later approved by the quality assurance team.
Each sample was labeled with a unique barcode number.
The barcode labels withstand the freezing procedure and
were validated for use in liquid nitrogen tanks. The location
of the cryopreserved samples was maintained in the BMR,
and the inhouse developed Regen software helped rapid and
accurate retrieval.
All documents relating to cell bank manufacturing, like
batch manufacturing record, cell harvest details, freezing
records, phenotypic characterization, viability data, and the
detailsofthemasterandworkingcellbankandtheirlocation
were made available for review by the quality assurance team
and then archived for future reference.
4. Results
4.1. Growth Kinetics and Immunophenotyping. Umbilical
cords from 5 diﬀerent donors (gestational ages 38–40 weeks)
were obtained from maternity hospitals after normal or
cesarean deliveries for generation of UCMSCs. All maternal
blood samples tested negative for infectious disease markers.
MSCs were successfully isolated from all the ﬁve cords
processed irrespective of the sex of the baby, gestation, and
ethnicity (Table 1). Data of cell counts at passage 1 of all
the ﬁve samples is also shown in Table 1, and it is clear that
we could obtain about 40–50 million cells from about 7 to
8cms of the cord used for processing. UCMSCs started to
migrate from the explants within 10 to 15 days and displayed
a homogenous ﬁbroblast-like morphology (Figure 1). Flow
cytometry studies showed that more than 90% of the6 Stem Cells International
UCMSCs displayed uniform mesenchymal stem cell markers
such as CD73, CD105, CD44, and CD29. UCMSCs were
negative for haematopoietic and endothelial markers such
as CD45, CD14, CD31, and vWF. Expression of HLA-DR
antigen was not expressed although the cells expressed HLA-
ABC antigen. It is important to note that UCMSCs also
expressed the stem cell marker SSEA-4 (Figure 2, Table 2).
Viability of the cells was determined to be more than 90%
by 7-AAD dye exclusion method using ﬂow cytometry.
4.2. Quality Control Tests. Creation of a master cell bank
was the ﬁrst step in the establishment of banking. A
master cell bank was generated from each case wherein
cells were cryopreserved at passage 1 after about 40 days
in culture. Cells were cryopreserved at a concentration of
1-2 × 106/mL in 1.8mL cryovials. Approximately 10–15
vials were made per sample, and one vial from the master
cell bank was allocated for quality control testing such as
immunophenotyping and viability studies. All the cells used
for generation of master cell bank were free of microbial and
mycoplasma contamination.
4.3. Cryopreservation and Documentation. UCMSCs that
were stored in liquid nitrogen containers provided a
secure storage environment and maintained temperatures
of −196◦C satisfactorily. The liquid nitrogen container was
connected to a data logger which recorded the storage
temperature in a dynamic mode. UCMSCs were frozen
till the temperature reached −150◦C before placing into
liquid nitrogen container. Freezing records were maintained
satisfactorily for all the samples. At the time of release from
quarantine, the cells were certiﬁed as being sterile, free from
mycoplasma and endotoxin.
4.4. Stability Studies. UCMSCs with a pre-freeze viability of
98-99% and biomarker expression of 98% were stored in
liquid nitrogen for a period of 1 month, 6 months, 1 year,
2 years, and 3 years. Upon thawing, the cell count, viability,
and immunophenotyping performed at every time point up
to three years are shown in Table 3.U C M S C sc r y o p r e s e r v e d
for 3 years in liquid nitrogen showed a negligible drop in
the cell count and viability as compared to the earlier time
points (Table 3). UCMSCs did not express HLA-DR antigen
pre- and postthawing (Figure 3) at all time points.
5. Discussion
MSCs are multipotent cells that have the ability to give rise
to diﬀerent cell types in the human body. They have a very
vast potential to serve as a new research tool to support
clinical applications for the future. They have been isolated
by various groups from diﬀerent regions of the cord, namely,
the perivascular region, the intervascular region, and also
the subamnion. Sarugaser et al. reported the isolation of
mesenchymal stem cells from the perivascular region of
the umbilical cord [17] whereas Covas et al. reported the
isolation of mesenchymal stem cells from the umblical vein
[18]. In our study, we have isolated MSCs having ﬁbroblast-
like morphology and expressing cell surface markers such
as CD73, CD105, CD44, and CD29 from Wharton’s jelly
portion of the umbilical cord tissue. We have also shown
that UCMSCs expanded in culture remain viable in liquid
n i t r o g e ne v e na f t e rc r y o p r e s e r v a t i o nf o ru pt o3y e a r s
although studies on prolonged cryopreservation periods are
proposed to be continued.
Several studies, including our own, have shown that
MSCs are immunomodulatory in nature and are expected
to play a major role in transplantation biology opening up
new promising avenues for them to be used in the allogeneic
settings [16, 19–21].
Due to their immunomodulatory properties, in addition
to their regenerative potential, MSCs are currently being
explored in other therapeutic approaches such as to improve
haematopoietic reconstitution after HSCT and to overcome
GVHD upon allogeneic transplantation [22, 23]. Le Blanc
et al. [23] have reported on the use of haploidentical
MSC in conjunction with allogeneic hematopoietic stem
cell transplantation to enhance engraftment. All patients
achieved neutrophil and platelet engraftment and 100%
donor chimerism. Osiris therapeutics have conducted a
phase 1 clinical trial to study the eﬀect of MSCs on
haematopoietic stem cell engraftment. The MSC infusions
were well tolerated, and there were no drug-related serious
adverse events and all patients achieved neutrophil engraft-
ment [24]. Both of these studies show the safety of MSC
infusion during hematopoietic stem cell transplantation.
Osiris therapeutics is also conducting clinical trial using
MSCs (Prochymal) for treatment of resistant Crohn’s disease
which is currently ongoing [25]. Hemorrhagic cystitis is
associated with HSCT, and its incidence varies from <10%
to more than 70%. Ringd´ en et al. [26] have used MSCs to
heal such therapy-induced tissue toxicity. In ﬁve of the seven
patients, the severe hemorrhagic cystitis cleared after MSC
infusion, and gross hematuria disappeared after median 3
(1–14)days.ThisstudyshowsthatMSCsisanoveltreatment
thatmaybeusedforGVHD,tissuetoxicity,andhemorrhages
because of its immune inhibitory and anti-inﬂammatory
eﬀects. MSCs have also been used for regeneration of the
myocardium after myocardial infarction [27, 28]. We have
previously reported our ﬁndings on the use of MSCs in
patients undergoing coronary bypass surgery [28]. Our
study showed that transepicardial injections of MSCs were
safe and feasible, correction of perfusion defect was also
observed although no signiﬁcant change was observed in
the ejection fraction. Chen et al. [29] have also reported
improvement in cardiac function of infarcted myocardium
with intracoronary transplantation of human mesenchymal
stem cells identiﬁed by noninvasive and cardiac electrome-
chanical mapping. Williams et al. [30] have shown that
transcatheter, intramyocardial injection of autologous bone
marrow preparations in patients with chronic ischemic
cardiomyopathy was welltolerated and produced functional
recovery in scarred myocardium and reverse remodeling
of the LV chamber. Encouraging results have also been
seen when MSCs were used for neuronal treatment [31].
Venkataramana et al. [32] have reported a clinical study inStem Cells International 7
which seven Parkinson’s disease patients were transplanted
with MSCs into the sublateral ventricular zone by stereotaxic
surgery. Results showed that injection of MSCs was safe,
and no serious adverse events occurred after stem cell
transplantation. MSCs have also been used for treatment of
osteogenesis imperfecta by Horwitz et al. [20].
A well-designed manufacturing record helps with ready
retrieval of the banked units and locating the position of
the units, besides helping us to capture all the intricate
data during the entire culturing process. This will help
designating speciﬁc storage location for each unit which in
the future will prevent wrong units from being retrieved.
Such details are also available in our locally designed
software Regen. Adequate care is taken to prevent cross-
contamination, and mixup as per the guidelines in force for
cell therapy manufacture.
Theestablishmentofvariousprocessesandproceduresin
thesetting upof theexperimentalbankhasbeenworthwhile.
While a detailed costing is being done, it appears that the
expenses involved in maintenance of cell cultures up to
passage 1, transportation, infectious disease testing, and
cryopreservation would likely be in the range of $1000–1200,
which excludes infrastructure, maintenance, and manpower
cost.
We have shown that appropriate maintenance of biologi-
calcharacteristicsanduniformityofthecellsispossibleusing
traditional cryopreservation methods. Our studies have
demonstrated that it is possible to generate and bank large
numbers of UCMSCs for regenerative medicine applications
for future use. The establishment of a stem cell bank hav-
ing well-characterized and “ready-to-use” allogeneic MSCs
could be promising and attractive to clinical researchers.
6. Conclusion
Our results show that simple and appropriate validated pro-
tocols for cord tissue processing under good manufacturing
conditions can help in the development of cost-eﬀective
banking of UCMSCs.
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